Aptabio Therapeutics Inc. (293780)
Market Open
7 Aug, 06:30
KRX SM KRX SM Primary ₩
5,570. 00
-290
-4.9488%
₩
227.15B Market Cap
- P/E Ratio
- Div Yield
61,586 Volume
- Eps
₩ 5,860
Previous Close Want to track 293780 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
293780 trading today lower at ₩5,570, a decrease of -4.9488% from yesterday's close, completing a monthly increase of 11.5115% or ₩575. Over the past 12 months, 293780 stock lost -40.4278%.
293780 is not paying dividends to its shareholders.
The last earnings report, released on Feb 06, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Aptabio Therapeutics Inc. has completed 1 stock splits, with the recent split occurring on Aug 24, 2021.
The company's stock is traded on one exchange.
Aptabio Therapeutics Inc. (293780) FAQ
What is the stock price today?
The current price is ₩5,570.00.
On which exchange is it traded?
Aptabio Therapeutics Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 293780.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 227.15B.
Has Aptabio Therapeutics Inc. ever had a stock split?
Aptabio Therapeutics Inc. had 1 splits and the recent split was on Aug 24, 2021.
Aptabio Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | KR7293780003 ISIN |
| KR Country | 41 Employees | - Last Dividend | 24 Aug 2021 Last Split | - IPO Date |
Overview
AptaBio Therapeutics Inc. is a biotechnological entity that focuses on the discovery and development of innovative therapeutics. The company specializes in the creation of selective inhibitors targeting the NOX family of enzymes and aptamer-based anti-cancer drugs. Founded in 2009, AptaBio Therapeutics has its headquarters in Yongin-Si, South Korea. It champions the research and development of treatment solutions for a range of diseases, leveraging advanced genetic engineering and molecular biology techniques to craft drugs that aim to improve the quality of life for patients worldwide.
Products and Services
- Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent: These products cater to the scientific and medical need for effective transfection agents. They are designed for the safe and efficient delivery of DNA or RNA into eukaryotic cells, facilitating gene expression and manipulation studies in the fields of molecular biology and genetic engineering. Their applications span from basic research to the development of gene therapies and vaccines.
- PX-115: A product candidate in development focusing on the treatment of diabetic nephropathy. PX-115 represents AptaBio's commitment to addressing the complications arising from diabetes, showcasing its innovative approach to intercept and treat kidney damage caused by the long-term impact of diabetes.
- APX-1004: Another significant product candidate that targets diabetic retinopathy. APX-1004 embodies AptaBio's efforts in combating vision loss due to diabetes, showcasing the company's pursuit of therapeutic options to prevent and mitigate one of the common and devastating complications of diabetes.
- APX-311: Dedicated to the treatment of non-alcoholic steatohepatitis (NASH), APX-311 is part of AptaBio's therapeutic pipeline aimed at confronting metabolic disorders. This drug candidate highlights the company’s endeavors in tackling liver health issues with innovative and selective pharmacological interventions.
Contact Information
Address: Heungdeok IT Valley, 13
Phone: 82 3 1365 3693
Website: https://www.aptabio.com
